Do you want to read an article? Please log in or register.
The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort
Leukemia
Related content
Leukemia
Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial
Leukemia
Ashaye A, Shi L, Aldoss I, Montesinos P, Vachhani P, Rocha V, Papayannidis C, Leonard JT, Baer MR, Ribera JM, McCloskey J, Wang J, Gao S, Rane D, Guo S
doi: 10.1038/s41375-025-02608-4
Leukemia
Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1-45 years: a Danish cohort study
Leukemia
Nielsen CG, Als-Nielsen B, Albertsen BK, Davídsson ÓB, Dimitrijevic A, Hjalgrim H, Ifversen M, Lundgren L, Lynggaard LS, Olsen M, Overgaard UM, Rank CU, Rathe M, Rostgaard K, Schmiegelow K, Andrés-Jensen L
doi: 10.1038/s41375-026-02873-x
Lymphoma
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial
Lancet Haematol
Northend M, Wilson W, Ediriwickrema K, Clifton-Hadley L, Qian W, Rana Z, Martin TL, Townsend W, Young M, Miall F, Cunningham D, Walewski J, Ferhanoglu B, Linton K, Johnston A, Seymour JF, Linch DC, Ardeshna KM
doi: 10.1016/S2352-3026(25)00034-1
Leukemia
Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients
Blood Cancer J
Alsugair A, Gauto Mariotti E, Alhousani MM, Fathima S, Yousuf M, Bolarinwa A, Foran J, Mangaonkar AA, Litzow M, Murthy H, Sproat L, Palmer J, Matin A, Ayala E, Slack J, Porrata L, Iqbal M, Khera N, Punwani N, Kenderian S, Chhabra S, Hogan WJ, Shah MV, Alkhateeb HB, Gangat N, Patnaik M, Tefferi A
doi: 10.1038/s41408-025-01359-w
COMMENTED
Further Publications
ASSOCIATION BETWEEN TYPE AND LOCATION OF GERMLINE BRCA1/2 PATHOGENIC OR LIKELY PATHOGENIC VARIANTS WITH PHENOTYPE AND PROGNOSIS IN YOUNG PATIENTS WITH BREAST CANCER: RESULTS FROM AN INTERNATIONAL COHORT STUDY
★ 2
Recommended and commented by
Dr Andreas Müller, Faculty Member
Ann Oncol
Toss A, Blondeaux E, Tenedini E, Bonamici L, Graffeo R, Livraghi L, Villarreal-Garza C, Molho RB, Kwong A, Balmana J, Wildiers H, Agostinetto E, Phillips KA, Pogoda K, Renaud T, Rousset-Jablonski C, Ferrari A, Moore HCF, Peccatori FA, Paluch-Shimon S, Fruscio R, Micheri C, Wong SM, Cui W, Vernieri C, Lee M, De Marchis L, Couch FJ, Del Mastro L, Puglisi F, Meireles PA, Kemp Z, Matikas A, Plichta J, Del Pilar Estevez-Diz M, Di Meglio A, Cichowska-Cwalinska N, Gianni C, Yerushalmi R, Sanchez-Bayona R, Mrinakova B, Matos L, Bianchini G, Caleffi M, Krivokuca A, Abdou Y, Mariño-Mariño M, Parokonnaya A, Okano M, Antone N, Saavedra C, Sonnenblick A, Duchnowska R, Pais HL, Harbeck N, Cortesi L, Delucchi V, De Angelis C, Lambertini M
doi: 10.1016/j.annonc.2025.11.004
Lung, Respiratory and Thoracic Cancer
Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study
Transl Lung Cancer Res
Auclin E, Du Rusquec P, Albarran-Artahona V, Aboubakar F, Gerber H, Epaillard N, Recondo G, De Giglio A, Berthou H, Laguna JC, Gorria T, Blaquier JB, Jimenez-Munarriz B, Tagliamento M, Di Federico A, Sacco G, Minatta J, Girard N, Moran-Bueno T, Lopez-Castro R, Besse B, Mezquita L
doi: 10.21037/tlcr-24-881
Multiple Myeloma (MM)
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial
Lancet Haematol
Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV, DREAMM-7 trial study group
doi: 10.1016/S2352-3026(25)00163-2
Leukemia
Similar Outcome With Haploidentical, Matched Sibling, or Matched Unrelated Donor Hematopoietic Cell Transplantation for Adult Patients With Adverse-Risk TP53-Mutated Acute Myeloid Leukemia in First Remission: A Comparative Study From the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Am J Hematol
Ru Y, Chen J, Ferhat AT, Labussière-Wallet H, Gedde-Dahl T, Kröger N, Socié G, Yakoub-Agha I, Eder M, Mielke S, Wu D, Mohty M, Ciceri F, Gorin NC
doi: 10.1002/ajh.70069
Leukemia
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry
Leukemia
Alfonso-Pierola A, Martinez-Cuadrón D, Rodríguez-Veiga R, Gil C, Martínez-Sánchez P, Bernal T, Benavente C, Romero-Riquelme MA, Serrano-Lopez J, Bergua JM, García-Boyero R, Tormo M, Herrera P, Sossa-Melo CL, Pérez-Simon JA, Rodríguez-Medina C, Bass-Maturana MF, López-Lorenzo JL, Algarra-Algarra L, Vidriales-Vicente B, Pérez-Encinas M, Barrios-García M, Vives S, Sayas-Lloris MJ, Capurro M, Hidalgo S, Olave M, Cuervo-Lozada D, Lavilla-Rubira E, Casado F, Mena-Durán A, Valero-Nuñez M, Casado-Calderón S, Balerdi A, Torres V, Fernández R, Noriega V, Stevenazzi M, Labrador J, León-Maldonado P, de Rueda-Ciller B, Arce-Fernández O, Amigo ML, Raposo-Puglia JÁ, Solé M, Boluda B, Ayala R, Barragán E, Montesinos P, PETHEMA Group
doi: 10.1038/s41375-025-02744-x